



# Correction to: REal world Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

Christian Domingo Ribas<sup>1,2</sup> · Teresa Carrillo Díaz<sup>3,4</sup> · Marina Blanco Aparicio<sup>5</sup> · Eva Martínez Moragón<sup>6</sup> · David Banas Conejero<sup>7</sup> · M. Guadalupe Sánchez Herrero<sup>7</sup> on behalf of the REDES Study Group

© The Author(s) 2021

## Correction to: Drugs

<https://doi.org/10.1007/s40265-021-01597-9>

**The members of the REDES Study Group** whose names are currently provided as:

Mariana Muñoz Esquerro, Héctor Cabrerizo Carreño, Gemma López Saiz, Celia Pinedo Sierra, Javier González Barcala, Purificación Pérez López Carona, Jacinto Ramos González, Javier Martín Puentes, Gregorio Soto Campos, Francisco Pérez Grimaldi, Juan Luis García Rivero, Celia Gueierrez Villegas, Idoia Salinas Garrido, Cleofé Fernández Aracil, Luis Puente Maestu, Ángela Gómez Sacristán, Miguel Díaz Palacios, Eusebi Chiner Vives, Sandra Vañes Baños, Rocío Díaz Campos, Ismael García Moguel, Carmen Montero Martínez, María Fernandez Marrube, Tamara Hermida Valverde, Nuria Marina Malanda, Ana Gómez Larrauri, Antonio García Dumpiérrez, Rodolfo Castillo Sainz, Nancy Ortega Rodríguez, Lourdes Almeida Quinatan, Luis Cabanes López, Santiago Quirce Gancedo, Javier

Domínguez Ortega, David Romero Ribate, Daniel Laorden Escudero, Antolin López Viña, Andrea Trisán Alonso, Teresa Caruana Careaga, Ana Gómez-Bastero Fernández and Lucía Marín Barrera.

Should be provided as:

Mariana Muñoz, Héctor Cabrerizo, Gemma López, Celia Pinedo, Javier González-Barcala, Purificación Pérez-López-Carona, Jacinto Ramos-González, Javier Martín-Puentes, Gregorio Soto-Campos, Francisco Pérez-Grimaldi, Juan Luis García-Rivero, Celia Gueierrez-Villegas, Idoia Salinas-Garrido, Cleofé Fernández-Aracil, Luis Puente-Maestu, Ángela Gómez-Sacristán, Miguel Díaz-Palacios, Eusebi Chiner-Vives, Sandra Vañes, Rocío Díaz-Campos, Ismael García-Moguel, Carmen Montero, María Fernandez-Marrube, Tamara Hermida-Valverde, Nuria Marina-Malanda, Ana Gómez-Larrauri, Antonio García-Dumpiérrez, Rodolfo Castillo-Sainz, Nancy Ortega, Lourdes Almeida, Luis Cabanes, Santiago Quirce, Javier Domínguez-Ortega, David Romero, Daniel Laorden, Antolin López-Viña, Andrea Trisán, Teresa Caruana-Careaga, Ana Gómez-Bastero and Lucía Marín-Barrera.

The original article can be found online at <https://doi.org/10.1007/s40265-021-01597-9>.

✉ Christian Domingo Ribas  
cdomingo@tauli.cat

<sup>1</sup> Servei de Pneumologia, Corporació Sanitària Parc Taulí, Parc Taulí s/n, Sabadell, 08208 Barcelona, Spain

<sup>2</sup> Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

<sup>3</sup> H. Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

<sup>4</sup> Universidad de Las Palmas Gran Canaria, Las Palmas de Gran Canaria, Spain

<sup>5</sup> H. Universitario A Coruña, A Coruña, Spain

<sup>6</sup> H. Universitario Doctor Peset, Valencia, Spain

<sup>7</sup> Specialty Care Medical Department, GlaxoSmithKline, Madrid, Spain

**Section 1.** Introduction, third paragraph, fifth sentence, which currently reads:

However, several single-centre real-life studies have shown evidence of the effectiveness of mepolizumab [15–18]

Should read:

Also, several single-centre real-life studies have shown evidence of the effectiveness of mepolizumab [15–18]

**Section 1.** Introduction, fourth paragraph, second sentence, which reads:

On the other hand, it has also been postulated that the lower the peripheral blood eosinophil value achieved by biological treatment, the better the clinical outcome.

Should be deleted.

**Section 2.2** Outcome, fifth sentence, which currently reads:

Two stratifications were carried out to baseline eosinophil levels: by ranges ( $< 150$  eosinophils/ $\mu\text{L}$ ,  $\geq 150$  and  $< 300$ / $\mu\text{L}$  and  $\geq 300$  and  $< 500$  eosinophils/ $\mu\text{L}$  at treatment initiation) and by lower thresholds:  $\geq 150$  eosinophils/ $\mu\text{L}$ ,  $\geq 300$  eosinophils/ $\mu\text{L}$ ,  $\geq 500$  eosinophils/ $\mu\text{L}$  and  $\geq 700$  eosinophils/ $\mu\text{L}$  at treatment initiation).

Should read:

Two stratifications were carried out to baseline eosinophil levels: by ranges ( $< 150$  eosinophils/ $\mu\text{L}$ ,  $\geq 150$  eosinophils/ $\mu\text{L}$  and  $< 300$  eosinophils/ $\mu\text{L}$ ,  $\geq 300$  eosinophils/ $\mu\text{L}$  and  $< 500$  eosinophils/ $\mu\text{L}$  and  $\geq 700$  eosinophils/ $\mu\text{L}$  at treatment initiation).

**Section 2.3** Study Measurements, second paragraph, second sentence, which currently reads:

For this, patients were grouped according to their baseline blood eosinophil counts ( $\geq 150$  cells/ $\mu\text{L}$ ,  $\geq 300$  cells/ $\mu\text{L}$ ,  $\geq 500$  cells/ $\mu\text{L}$  and  $\geq 750$  cells/ $\mu\text{L}$ ), and baseline blood eosinophil ranges ( $< 150$  cells/ $\mu\text{L}$ , 150–299 cells/ $\mu\text{L}$ , 300–499 cells/ $\mu\text{L}$ , 500–699 cells/ $\mu\text{L}$  and  $\geq 700$  cells/ $\mu\text{L}$ ).

Should read:

For this, patients were grouped according to their baseline blood eosinophil counts ( $\geq 150$  cells/ $\mu\text{L}$ ,  $\geq 300$  cells/ $\mu\text{L}$ ,  $\geq 500$  cells/ $\mu\text{L}$  and  $\geq 700$  cells/ $\mu\text{L}$ ), and baseline blood eosinophil ranges ( $< 150$  cells/ $\mu\text{L}$ , 150–299 cells/ $\mu\text{L}$ , 300–499 cells/ $\mu\text{L}$ , 500–699 cells/ $\mu\text{L}$  and  $\geq 700$  cells/ $\mu\text{L}$ ).

**Section 2.4** Sample Population Size Calculation, fourth sentence, which currently reads:

The power analysis considered a sample size of 350, after assuming an assumed 10% of missing data, meaning that we would need to include 320 patients.

Should read:

The power analysis considered a sample size of 350, after assuming a 10% of missing data, meaning that we would need to include 320 patients.

**Section 3.2** Previous Treatment, second paragraph, second sentence, which currently reads:

Two hundred and ninety-four (92.5%) of the patients continued to receive mepolizumab; three patients (0.9%) discontinued mepolizumab treatment 6 months, the main reason being inadequate control and adverse events (Table 2).

Should read:

Two hundred and ninety-four (92.5%) of the patients continued to receive mepolizumab; three patients (0.9%) discontinued mepolizumab treatment at 6 months, the main reason being inadequate control and adverse events (Table 2).

## References

Reference 1. The authors should be listed as

Domingo Ribas C, Sogo Sagardia A, Prina E, Sicras Mainar A, Sicras Navarro A, Engroba Teijeiro C.

Reference 3. The first author should be listed as

Plaza Moral V.

Reference 12. Citation details should read

Allergy. 2019;74(9):1716–1726. <https://doi.org/10.1111/all.13850>

Reference 13. The authors should be listed as

Enríquez-Rodríguez AI, Hermida Valverde T, Romero Álvarez P, López-González FJ, Gullón Blanco JA, Expósito Villegas AR, et al.

Reference 38. The authors should be listed as

Álvarez Gutiérrez FJ, Blanco Aparicio M, Plaza V, Cisneros C, García Rivero JL, Padilla A, et al.

The original article has been update.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction

---

in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory

regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.